Last reviewed · How we verify
NCT06120647
Molecular Mechanisms Underpinning Sarcopenic Obesity
trial testing Essential amino acids (EAA) in Sarcopenic Obesity in 60 participants. Status unknown.
15 December 2025
Quick facts
| Lead sponsor | The Swedish School of Sport and Health Sciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 28 January 2020 |
| Primary completion | 15 December 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Essential amino acids (EAA) — full drug profile →
Conditions studied
- Sarcopenic Obesity — all drugs for Sarcopenic Obesity →
- Obesity — all drugs for Obesity →
- Sarcopenia — all drugs for Sarcopenia →
- Aging — all drugs for Aging →
Sponsor
The Swedish School of Sport and Health Sciences
Who can join
Adults 18 to 80, any sex, with Sarcopenic Obesity or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The coexistence of obesity and sarcopenia results in sarcopenic obesity, a high-risk geriatric condition associated with metabolic perturbations and several co-morbidities. Despite the rising numbers of older adults diagnosed with sarcopenic obesity, few studies have characterized this condition on the muscle cell and systemic level. This study sought to comprehensively assess the influence of sarcopenic obesity on muscle and blood-related parameters and compare it to non-sarocopenic obese and non-sarcopenic lean older adults.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06120647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcopenic Obesity
Currently open trials in the same condition.
- NCT07154719 — GLP-1R Actions on Muscle and the Skeleton · Phase 4 · recruiting
- NCT07035483 — Changes in Fat and Muscle Tissue Function and Their Impact on Metabolic Health After Bariatric Surgery · active not recruiting
- NCT06600581 — Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness · Phase 2 · active not recruiting
- NCT06826963 — Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study · NA · recruiting
- NCT06822504 — Prevalence of Sarcopenic Obesity in COPD · recruiting
Other The Swedish School of Sport and Health Sciences trials
Trials by the same sponsor.
- NCT07461194 — Timing of Broccoli Sprout Intake to Improve Exercise Performance · NA · not yet recruiting
- NCT07407829 — Step by Step Back - A Feasibility Study of a Physical Activity Intervention for Adults With Stress-related Exhaustion · NA · recruiting
- NCT06245538 — Exercise Intensity on Brain & Mental Health in Stress · NA · completed
- NCT06145152 — Adaptive Training Recommendations for Improved Physical Performance · Phase 1 · unknown
- NCT05070585 — Isothiocyanates and Metabolic Health · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06120647 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Swedish School of Sport and Health Sciences
- Last refreshed: 11 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06120647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing